Our integrated approach supports early and near-launch pipeline assets and current portfolio products across all stages of development. Certara brings together advanced analytics, modeling and long-standing relationships in the payer community to help market access teams make better informed decisions and clearly demonstrate value.
Market Access, Pricing and Reimbursement
Establish and communicate your healthcare product’s value
Certara’s Market Access Pricing and Reimbursement Consulting services empower global and U.S. market access teams to achieve strategic success. By optimizing product value, positioning, and evidence synthesis, we ensure your product’s value is effectively demonstrated across all stages of the reimbursement journey.
Learn more about market access pricing and reimbursement
An integrated approach to market access pricing and reimbursement
Evidence-based pricing strategies
Our qualitative and quantitative methods enable precise pricing strategies that enhance revenue, access, and demand.
Valuable payer insights
Input from a trusted network of 100+ vetted payer and channel decision makers who are often current voting members of P&T committees or medical policy committees
Early development support
Strategic guidance on the pricing and reimbursement related assumptions for the target product profile (TPP) and market access landscape assessment in early stages of development.
Certara: leading innovation in pricing and market access
At Certara, we combine scientific rigor with empathetic understanding of public health decision-makers’ challenges. Here’s how we stand out:
Market access & pricing solutions for all phases of drug development
Pre-clinical
- Candidate drug selection
- Comparator in clinical trials
- Market potential assessment
- Market landscape assessment (ongoing through all phases)
Early clinical (phase I and II)
- Clinical trial design input
- Go/no-go decisions on continued product development
- Indication prioritization
- First price scenarios
- Pricing/reimbursement barriers
- Initial segmentation
Late clinical (phase III and launch prep)
- Payer value story and messaging
- Global pricing strategy
- Launch sequence
- Pricing, contracting and rebate strategy
- Global value/AMCP dossier
- Support material for regions/affiliates
Post-launch (lifecycle management)
- Indication expansion
- Biosimilar/generic entry
- Price changes
- Ongoing contract/rebate strategy
- Entry to new markets
- New formulation or device
Meet our market access leaders
1 / 1
Experts
Maximilian Vargas, PhD, MBA
Vice President, US Access Strategy
Maximilian Vargas, PhD MBA, is a Vice President, US Access Strategy within Certara’s Evidence and Access Group since 2012. He brings both scientific training and experience in healthcare product development that are important for evidence-based value and access strategies for pipeline and marketed products.
ConnectResources for your market access journey
View allContact our market access and pricing experts
Certara is dedicated to guiding you through every stage of the pricing, reimbursement, and market access journey. Our combination of strong science and understanding of public health decision-makers’ challenges is the key to effective market access and pricing. We assess value of health interventions with an array of methods.
Proven expertise in crafting evidence-based strategies
Comprehensive support from early development to post-launch
A trusted partner for navigating complex global payer landscapes
Send an inquiry
Explore other Certara products and services
FAQs about market access and pricing consulting
What is the role of Certara in market access and pricing?
Certara provides strategic guidance to optimize product value, pricing, and access across all stages of the reimbursement journey.
How does Certara aid in early development?
We identify unmet needs, value drivers, and optimal launch strategies to maximize commercial success.
What post-launch strategies does Certara offer?
We help defend market leadership, adapt pricing strategies post-patent expiry, and monitor global pricing impacts.
